Journal: PLoS ONE
Article Title: Systemic Administration of Abeta mAb Reduces Retinal Deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model
doi: 10.1371/journal.pone.0065518
Figure Lengend Snippet: Aβ (4G8+, red) and activated complement C3 (detected with clone 2/11+, #HM1065, Hycult Biotech., , green), cross reactivity to retinal sections at 9 months, (after 3 months dosing): (A) negative control (PBS treated), 6F6, at 60 µg dose (B) and 600 µg dose (C). Scalebar = 25 µm), PR = phototreceptors/outer segments, RPE = retinal pigment epithelium, CHO = choroid, DAPI = 4',6-diamidino-2-phenylindole. Left hand panel (A), (B), (C) is stained with DAPI, right hand panel (A), (B), (C), is without DAPI staining. Aβ (D), and activated complement C3, (E), deposition in the RPE/Bruch’s membrane of cfh−/− mice, are plotted as differences from vehicle control with 95% confidence intervals (CI) after therapeutic treatment. Data in graphs (D) and (E) show data at an intermediate time point, after 7 months of age (7MO), 1 month (+4w) after treatment as well as at the end of the regime at 9 months of age (9MO), 3 months (+12w) after treatment. Data in graphs (D) and (E) also shows wild type (WT) mice treated with 6F6 (WT6F6) after 7 months of age (7MO), 1 month (+4w) after treatment. Mice dosed with 6F6 show a dose dependent significant reduction, (asterisks, see text for levels of significance), in Aβ deposition at 60 µg and 600 µg and in activated C3 deposition at 600 µg compared compared to those treated with vehicle, (D) at 9 months of age (9MO), 3 months (+12w) after treatment.
Article Snippet: Although the same primary antibody was used for the detection of Aβ deposition as in the remainder of the study, (4G8, ), this was biotin-labelled and detected with Alexa Fluor 488 streptavidin, and a different primary antibody was used to detect total C3, (Hycult biotech, cat# HP8022) a rabbit polyclonal anti-Rat C3 antibody which gave low background for IHC staining, (data from this study is described solely in the final part of the Results section and was the only occasion that the antibody combination described above was used in this work).
Techniques: Negative Control, Staining